FDA clears Sony's surgery video-sharing platform

operating room
Previously available in Europe, Sony’s electronics unit said it counts more than 500 operating room installations in the U.K., Belgium, Sweden and other locations. (Pixabay)

Multinational conglomerate Sony has received a clearance from the FDA for its digital workflow collaboration platform for hospital operating rooms and catheter labs.

The company’s NUCLeUS software is designed to provide imaging management at 4K resolution as well as still images and patient data, plus it has the ability to capture and share live or archived surgical videos for teaching purposes.

"We are eager to put NUCLeUS in the hands of doctors, nurses and OR managers in the U.S. so they can experience first-hand how the platform can dramatically improve surgical collaboration and potentially contribute to better patient outcomes," Theresa Alesso, president of Sony Electronics' Pro division, said in a statement

Previously available in Europe, Sony’s electronics unit said it counts more than 500 OR installations in the U.K., Belgium, Sweden and other locations. 

The system ties together Sony’s previous medical offerings, including cameras, recording devices and surgical monitors, with a centralized, touchscreen dashboard. Additionally, the company plans to bring new, optional features to the scalable platform in the future.

RELATED: Sony-backed M3, Endeavour Vision unveil digital health investment funds

"With the ongoing development of unique 'smart applications,' NUCLeUS will continue to push the boundaries of what is possible in the OR," Alesso said.

The system also offers a “patient distraction” function aimed at reducing anxiety with music tracks and videos that can help provide a more relaxing atmosphere.

Suggested Articles

Testing programs initially slated to test hundreds or thousands have been scaled back or put on hold.

The FDA authorized CLEW Medical’s remote data monitoring system to help predict and identify COVID-19 patients at high risk for respiratory failure.

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.